Novo Nordisk regains Novorapid supply capacity

After a challenging period, Novo Nordisk can once again supply fast-acting insulin product Novorapid, Dagens Pharma reports.
Photo: Jacob Ehrbahn/Politiken
Photo: Jacob Ehrbahn/Politiken
by mikkel aabenhus hemmingsen, translated by catherine brett

Supply chain issues concerning Novo Nordisk’s fast-acting insulin product Novorapid (insulin aspart) have been resolved, industry media Dagens Pharma reports.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading